Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YHJ-7-52
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
YHJ-7-52 is a small molecule compound described in scientific literature as a selective inhibitor of matrix metalloproteinase 2 (MMP2). It is not an approved pharmaceutical drug and does not have any known brand names or commercial formulations. The compound has been studied primarily in preclinical research settings for its potential to modulate extracellular matrix remodeling by inhibiting MMP2 activity, which may be relevant in diseases such as cancer metastasis, fibrosis, and other pathological conditions involving tissue remodeling. There is no evidence that YHJ-7-52 has advanced to clinical trials or human use.
02
Targets
MMP14 (Matrix metalloproteinase 14)MMP2 (Matrix metalloproteinase-2)
Beyond the preview
Go deeper on YHJ-7-52.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YHJ-7-52.